KRBP — Kiromic Biopharma Balance Sheet
0.000.00%
- $2.82m
- $8.10m
Annual balance sheet for Kiromic Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.384 | 1.93 | 10.2 | 25.4 | 0.645 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.024 | 0 | — | 0.016 | 0 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 0.56 | 2.04 | 10.7 | 27.1 | 1.69 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.298 | 0.588 | 2.07 | 3.63 | 10.3 |
Other Long Term Assets | |||||
Total Assets | 0.876 | 2.65 | 12.8 | 30.7 | 12 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.611 | 0.674 | 1.47 | 3.41 | 13.3 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.611 | 0.674 | 1.47 | 3.41 | 17.7 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.265 | 1.98 | 11.4 | 27.3 | -5.77 |
Total Liabilities & Shareholders' Equity | 0.876 | 2.65 | 12.8 | 30.7 | 12 |
Total Common Shares Outstanding |